SCHEMBL1801749

SCHEMBL1801749

COc1nc(-c2c[nH]c3ncc(C4CCCCC4)cc23)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 2/20 0.39
▸ MAP4K1 Q92918 2/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ MAPK9 P45984 3/20 0.38
▸ MAPK8 P45983 2/20 0.38
▸ MAPK10 P53779 2/20 0.38
▸ CAMKK2 Q96RR4 1/20 0.37
▸ NTRK1 P04629 5/20 0.36
▸ KIT P10721 3/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ CDK2 P24941 2/20 0.35
▸ CCNT1 O60563 1/20 0.35
▸ CCNA2 P20248 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ DYRK1A Q13627 2/20 0.35
▸ CDC7 O00311 1/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ MAPK13 O15264 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797816 0.90 MEN1 (0.39) IL2MAP4K1PDGFRBPDGFRAMAPK9
SCHEMBL1799003 0.86 MAPK9 (0.40) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL1794527 0.83 MAPK8 (0.61) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL1794525 0.83 MAPK8 (0.61) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL1800688 0.82 MAPK8 (0.63) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL1800691 0.82 MAPK8 (0.63) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL8167221 0.80 MAPK9 (0.39) MAPK9MAPK8MAPK10NTRK1CDK2
SCHEMBL1796713 0.80 CAMKK2 (0.43) MAPK9MAPK8MAPK10CAMKK2ROCK1
SCHEMBL1796697 0.80 IL2 (0.44) IL2MAP4K1MAPK9MAPK8MAPK10
SCHEMBL1796868 0.79 CAMKK2 (0.39) MAP4K1MAPK9MAPK8MAPK10CAMKK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
EP-2125801-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE Eisai R&D Management Co., Ltd. (JP) 2009-12-02 — — EP disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 IL2 347/4885MAP4K1 46/4885PDGFRB 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback